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Abstract
Purpose The study aims to evaluate a series of patients
with initial diagnosis of ocular histoplasmosis syndrome
(OHS) with progression and response to treatments consistent with multifocal choroiditis (MFC).
Methods Retrospective review of nine patients referred for
management of recurrent OHS lesions. Serology panel was
conducted to rule out autoimmune and infectious causes.
Results Clinical examination revealed multiple small,
punched-out peripheral chorioretinal scars, and peripapillary atrophy. Histoplasma antigen/antibody was negative in
all patients. Fluorescein angiography and optical coherence
tomography confirmed active inflammation in five patients.
Immunomodulatory therapy (IMT) was initiated to control
active inflammation. While on IMT, visual acuity stabilized
or improved in three patients with no recurrence of CNV or
lesion activities over the follow-up period.
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Conclusions MFC may initially masquerade as OHS.
Clinical characteristics of recurrent MFC and absence of
histoplasma titer may lead to consideration of IMT and
other proper treatments for MFC.
Keywords Multifocal choroiditis . Ocular histoplasmosis
syndrome

Introduction
Differentiating between multifocal choroiditis (MFC) and
ocular histoplasmosis syndrome (OHS) may be challenging, especially if based solely on clinical examination. Both
may present with chorioretinal (CR) lesions and lack of
anterior chamber (AC)/vitreous inflammation [1]. Punchedout chorioretinal scars, peripapillary scarring, and choroidal
neovascularization are present in both conditions [2].
However, as the management of OHS differs tremendously
from that of MFC, it is important to make proper diagnosis.
The index study evaluates a series of patients whose initial
diagnosis was OHS. Patients underwent extensive review of
systems, uveitis diagnostic survey, a comprehensive examination, and targeted evaluation. The subsequent progression and response to treatments in all patients were
consistent with MFC.

Materials and methods
Nine patients were referred from January 2008 to June
2010 to one of the authors (QDN) for management of OHS.
Patients were diagnosed and managed as subjects with OHS
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in their primary institutes; laser photocoagulation/vascular
endothelial growth factor (VEGF) antagonists for recurrent
choroidal neovascularization (CNV) and episodic prednisone for lesions causing visual disturbances were prescribed. At the Wilmer Eye Institute, serology panel was
conducted to rule out autoimmune and infectious causes.
Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at initial and subsequent
visits.
The charts of eligible patients were reviewed to include
data regarding demographic features of each patient,
previous diagnosis of OHS and any concomitant diagnosis,
history of any relevant treatment to disease, and the length
of follow up. The results of comprehensive ocular examination, serologic workup for all possible inflammatory and
infectious conditions, as well as FA and OCT were
reviewed. Final diagnosis and treatment applied for each
patient was documented as well. Statistical summaries for
baseline characteristics were reported. The final diagnosis,
treatment regimen, and final outcomes for each patient were
presented.

Results
Eight women and one man with an age range of 26–
69 years (median: 38 years) were included in the study. Six
patients had a previous diagnosis of OHS, two had a likely
diagnosis of OHS or punctuate inner choroidopathy (PIC),
and one had a questionable diagnosis of uveitis and an
inflammatory/infectious process such as sarcoidosis or
OHS. Seven of the patients had a history of bevacizumab
injection to control CNV, one of whom also received laser
photocoagulation and photodynamic therapy; one had
photodynamic therapy as well as intraocular injection of
triamcinolone acetonide; the other one had photodynamic
therapy prior to bevacizumab injection. One patient had a
history of only laser photocoagulation to control CNV. The
patients were followed up at our institute for a period of
1.18–14.51 months (median; 3.16 months).
We carried out a comprehensive ocular examination as
well as serologic workup for all possible inflammatory and
infectious conditions based on the clinical findings.
Multiple small, punched-out peripheral CR scars and
peripapillary atrophy were noted in all patients. No
AC/vitreous inflammation was detected. None of them
had active CNV at the time of initial visit (Figs. 1 and 2).
Histoplasma antigen/antibody for all subjects was performed in the same clinical laboratory through the Johns
Hopkins University and Hospitals, and both antigen and
antibody were negative in all patients.
Rheumatoid panel and serology for Herpes simplex as
well as Herpes zoster were also negative. FA and OCT
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confirmed active inflammation (choroiditis without CNV)
in five patients. Table 1 shows the clinical and imaging
findings as well as serologic evaluation for each patient.
Based on the clinical examination and the result of
serologic evaluations that were nonrevealing for other
causes, a diagnosis of immune-mediated MFC was made
in seven patients. Patient 8 had a history of positive PPD
testing and ocular finding which might be consistent with
tuberculous choroiditis. We recommended the patient to be
evaluated for tuberculosis infection as well. For patient 9,
based on the clinical findings and negative serology for
histoplasmosis, it was most likely that he had CNV, which
is idiopathic in nature. There did not seem to be any active
CNV at the time of examination. Therefore, the patient was
advised to monitor his vision closely and be re-examined
regularly to look for any signs of CNV activity.
Immunomodulatory therapy (IMT) was initiated to
control the inflammation in five of the eight patients
(patients 1, 2, 5, 6, and 7). They received treatment from
1.84 to 6.22 months. Patient 3 had a complicated medical
history of scleroderma, graft-versus-host disease after an
allogenic bone marrow transplant for leukemia, history of
cytomegalovirus encephalopathy, and shingles. She was on
mycophenolate mofetil for scleroderma and graft-versushost disease at the time of initial visit. Considering the
underlying hematologic disease, we recommended a consultation with her hematologist/oncologist prior to starting
treatment for MFC. For patient 4, based on examination
and ancillary testing, it was most likely that she had
primary MFC rather than OHS or toxoplasmosis. We
decided to monitor the patient and would begin IMT
treatment to decrease the risk of recurrent inflammation if
active choroiditis or recurrent CNV reappeared. In addition,
VEGF antagonist would be employed as needed to provide
rapid control of any recurrent CNV.
While on IMT, visual acuity stabilized or improved in
patients 2, 5, and 6 with no recurrence of CNV or lesion
activities over the follow-up period. These three patients
were followed up for a period of 3.16, 1.84, and
5.69 months, respectively. Patient 1 had an episode of
visual disturbance in the right eye which was accompanied
with an enlargement of two previously detected lesions on
OCT. The disease activation was not controlled by increase
in the dose of IMT; therefore, the patient was enrolled in a
clinical trial of local treatment of another IMT. Patient 7
had a worsening of visual acuity in the right eye from 20/
200 to 20/320 after initiation of IMT (mycophenolate
mofetil). Considering the short period of IMT treatment
and slow treatment response in the case of IMT, we decided
to continue our recommended treatment and follow up the
patient every 4 weeks. The visual acuity improved to
20/200, 3 months after initiation of IMT and the dosage was
increased to 1.5 g twice a day at the last visit. Patient 4 and
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Fig. 1 The Optos™ P-200°
digital fundus image of patient 6
illustrates chorioretinal lesions
inferiorly in both eyes. Lesions
in the left eye are more
prominent than those in the
right eye. There is a yellowish
lesion just inferonasal to foveal
center of the left eye

9 had stable disease at the most recent visits and were thus
being observed on no IMT. As mentioned, patient 8 was
being evaluated by the Infectious Diseases Service for
possible tuberculosis infection. Since she did not have any
active lesion, we decided to observe her until a definitive
diagnosis was identified.
At the last visit, the visual acuity among all patients
has changed from 20/20–20/250 (median; 20/80) to
20/16–20/200 (median; 20/125) in the right eye and from
20/20–20/400 (median; 20/63) to 20/16–8/320 (median;
20/32) in the left eye.
Additional details on IMT and treatment response for
each patient are presented in Table 1. In addition, imaging
studies of patients with diagnosis of MFC showed decrease

in the amount of fluorescence of the lesions on autofluorescence among those being treated with IMT.

Fig. 2 a Fundus image of the right eye of patient 5 illustrates multiple
chorioretinal lesions, which concentrates within the macula. There is a
deep chorioretinal scar on the temporal aspect of foveal center with no
subretinal fluid. b, c Fluorescein angiography of right eye demonstrates classical choroidal neovascularization (CNV) filling pattern

with chorioretinal anastomosis in the center without prominent
leakage in early b and mid c phases. d, e Optical Coherence
Tomography of right eye shows hyperreflective substance within the
retinal pigment epithelium (RPE)/choroid complex, with no intraretinal edema

Discussion
Patients with MFC may masquerade as OHS. The index
study suggests that the diagnosis of OHS should not be
considered exclusively unless accompanied by positive
serology, absence of inflammation, and appropriate clinical
course for OHS. Even then, the patients should be followed
closely for progression of the lesions as the disease may be
of different entities. Our patients had many features that
resembled OHS. Peripheral and posterior pole scars like

20/20 RE 20/
400 LE

20/80 RE
20/63 LE

2/31.33/W/F/BE

Initial

Visual acuity

1/47.57/W/F/BE

Case no./age, yr/
race/sex/affected
eye

20/40 RE
20/32 LE

20/16 RE 20/
250 LE

Final

3.16

14.51

F/U
(mo)

No evidence of
iridocyclitis; no
inflammatory cells in
the vitreous

No evidence of iridocyclitis;
no inflammatory cells in
the vitreous

AC/vitreous reaction at
initial visit

Table 1 Demographic, clinical, and serologic characteristics of the patients

FA: RE: No evidence of
any leakage within the
foveal area; leakage of
two isolated lesions
LE: staining of the
fibrotic scar, no active
leakage
OCT: RE; RPE
disruption in areas
corresponded to the
two lesions
superonasal and
inferotemporal to the
fovea

FA: No leakage.
Autofluorescence: areas
of hyperfluorescence
surrounding various
lesions in RE
OCT: RE; Hyper
reflective scar tissue
involves the foveal
center, starting from
sub-RPE level extending to the inner plexiform layer

Histoplasma Antigen: N
Histoplasma Antibody: N
HSV type I IgG: P
HSV type II IgG: N
Muridase (Lysozome): N
ACE: N
RPR Screen: NR
FTA-ABS-Serum: NR
VZV IgG Antibody: P
Toxoplasma IgM: N
Toxoplasma IgG: N
EBV IgM: N
RE; Several chorioretinal
lesions within and
outside of arcade, nasal
to optic nerves and in
the inferonasal
quadrants
LE; Few chorioretinal
scars within and
outside of arcades, a
curvilinear area of
chorioretinal lesions in
temporal area
consistent with MFC

Imaging findings at
initial visit

Histoplasma Antigen: N
Histoplasma Antibody: N
Muramidase (Lysozyme): N
ACE: N
RPR Screen: NR
FTA-ABS-Serum: NR
ANA Screen: N
Anti-DNA: N
RNP Antibody: N
Smith Antibody:N
Anti-RO (SS-A): N
Anti-LA (SS-B): N
SCL-70: N
EBV IgG: P
Lyme Disease Antibody: N

Serologic findings at initial
visit

BE: Peripapillary
atrophy; multiple
pigmented,
chorioretinal lesions
scattering in the
peripheral retina
RE: 2 small yellowish,
deep chorioretinal
lesions, 1 superonasal
to the foveal center, 1
inferotemporal to the
foveal center
LE: A large fibrotic scar
in macula

Funduscopic findings at
initial visit

Past Ocular Treatment
Prednisone 80 mg/daily
for RE involvement.
Methotrexate was
added for 3 months
after LE involvement.
Methotrexate was
discontinued. With a
strong suspicion of PIC
she was kept on
prednisone
80 mg/daily

Past Ocular Treatment
Laser photocoagulation
and photodynamic
therapy for CNV as
well as intravitreal
injection of
bevacizumab
Treatments at the
Wilmer Eye Institute
Methylprednisolone
1,000 mg/IV a day for
3 days. Prednisone
60 mg/PO a day
tapered to 12.5 mg/
daily over the period of
6 months;
mycophenolate mofetil
2,000 mg/PO daily
increased to 2,500 mg/
PO daily after
4 months. Despite an
increase in the dose of
mycophenolate mofetil,
on repeated OCTs,
there were
enlargements of the 2
lesions in the right eye
compared to previous
OCTs
The patient was then
enrolled in a clinical
trial of local treatment
of sirolimus, which
helped to reduce the
size of the lesions and
allowed tapering of
prednisone

Treatment and clinical
course
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3/50.14/W/F/BE

20/250 RE
20/25 LE

20/160 RE
20/25 LE

1.18

No evidence of
iridocyclitis; no
inflammatory cells in
the vitreous
BE: Multiple
hypopigmented
chorioretinal spots in
the mid periphery
RE: Edema and
subretinal fibrosis
through the fovea
LE: Pigmentary changes
without edema through
the fovea

Histoplasma Antigen: N
Histoplasma Antibody: N
ANA Screen: N
Anti-DNA: N
RNP Antibody: N
Smith Antibody: N
Anti-RO (SS-A): N
Anti-LA (SS-B): N
HSV type I IgG: N
HSV type II IgG: N
VZV IgG Antibody: N
Toxoplasma IgM: N
Toxoplasma IgG: N
EBV IgG: N

FA: RE:
Hyperfluorescence and
leakage from many
hypopigmented spots
in the mid periphery as
well as mild leakage
from some of the
vasculature in the
peripheral retina; no
optic disk leakage or
staining,
hyperfluorescence in the
fovea corresponding to
the area of fibrosis
LE: Leakage from the
hypopigmented
peripheral spots; no
optic disk leakage or
staining, no macular
edema
OCT: RE: Intraretinal
edema through the
center of the fovea
LE: very mild intraretinal
edema

Past Ocular Treatment
Bevacizumab 4 injections
for CNV.
Treatment at the
Wilmer Eye Institute
We recommended a
consult with her
hematologist/
oncologist to evaluate
for a possible
hematologic
underlying disease
prior to initiation of
potential treatment for
multifocal choroiditis

Treatment at the
Wilmer Eye Institute
Mycophenolate mofetil
1 g/twice a day.
Prednisone tapered
after 10 days of
administration of
mycophenolate mofetil.
Three months later,
prednisone tapered to
20 mg. During the last
visit, funduscopic
examination revealed
stable findings of
multiple chorioretinal
lesions mainly in the
posterior pole. There
had been also a
decrease in the amount
of hyperfluorescence
on autofluorescence,
and a decrease in the
amount of RPE
disruption on OCTs in
both eyes

J Ophthal Inflamm Infect (2011) 1:55–63
59

20/200 RE
20/20 LE

20/63 RE
20/20 LE

20/20 RE
20/80 LE

5/38.01/W/F/BE

6/31.96/W/F/BE

Initial

Visual acuity

4/26.91/W/F/BE

Case no./age, yr/
race/sex/affected
eye

Table 1 (continued)

20/125 RE
20/125 LE

20/25 RE
20/16 LE

20/125 RE
20/20 LE

Final

5.69

2.83

1.68

F/U
(mo)

No evidence of
Iridocyclitis; no
inflammatory cells in
the vitreous

No evidence of
iridocyclitis; no
definite inflammatory
cells in the vitreous

No evidence of
Iridocyclitis; no
inflammatory cells in
the vitreous

AC/vitreous reaction at
initial visit

BE: Chorioretinal
lesions inferiorly, LE
worse than RE
LE: yellowish lesion
inferonasal to foveal
center

RE: Multiple
chorioretinal lesions,
much more in the nasal
aspect of retina. Deep
chorioretinal scar on
the temporal aspect of
foveal center with no
subretinal fluid and
two lesions in the
temporal peripheral
retina
LE: Chorioretinal lesions
in the nasal aspect of
the retina. Macula
appeared normal

RE: Multiple small
discrete pigmented
chorioretinal lesions
scattered in posterior
pole and throughout
the peripheral retina.
Atrophic changes and
subretinal fibrosis in
the macula
LE: Few scattered
chorioretinal lesions
limited mainly to nasal
area of optic nerve.
Ring of pigment next
to the foveal center
with no subretinal fluid
or hemorrhage

Funduscopic findings at
initial visit

Histoplasma Antigen: N
Histoplasma Antibody: N

Histoplasma Antigen: N
Histoplasma Antibody: N

Histoplasma Antigen: N
Histoplasma Antibody: N
Muramidase (Lysozyme):
N
ACE: N
RPR Screen: NR
FTA-ABS-Serum: NR
ANA Screen: N
HSV type I IgG: N
HSV type II IgG: N
EBV IgG: P
EBV IgM: N
Toxoplasma IgM: N
Toxoplasma IgG: N

Serologic findings at initial
visit

Past Ocular Treatment
Photodynamic therapy
and intraocular
corticosteroid followed
by one intravitreal
injection of
bevacizumab
Treatment at the
Wilmer Eye Institute
Mycophenolate mofetil
1 g twice a day. During
the most recent visit,
the lesions appeared to
be much less active.
On FA, there was no
evidence of leakage in
the macula of either
eye
Also, there had been
much decrease in the
amount of fluorescence
of macular lesions in
RE on AF

FA: RE: chorioretinal
anastomosis in foveal
center without
significant leakage
OCT: RE: Scar tissue
involved RPE and
photoreceptor layer, no
intraretinal edema
AF: RE:
hyperfluorescence
surrounding several
chorioretinal lesions

Past Ocular Treatment
Bevacizumab injections
for CNV
Treatment at the
Wilmer Eye Institute

Past Ocular Treatment
Bevacizumab2 injections
for CNV
Treatment at the
Wilmer Eye Institute
The patient was
monitored.
Immunomodulatory
therapy would be
started to decrease the
risk of inflammations
in case of recurrent
CNV in LE. Vascular
endothelial growth
factor antagonist would
be employed as well
when there is recurrent
CNV

Treatment and clinical
course

FA: RE: Multiple small
lesions scattered in
posterior pole and
throughout the
peripheral retina
without leakage. Scar
staining noticed at the
foveal center
LE: Classic CNV filling
pattern noticed without
leakage at late phase
OCT: RE: Multiple
lesions involve
different layers of
retina and sub-RPE in
some areas, including
foveal center which result in intra retinal
edema, more pronounced nasally
LE: presence of a PED

Imaging findings at
initial visit
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20/200 RE
20/25 LE

20/200 RE
20/400 LE

7/36.16/W/F/BE

8/69.22/W/F/BE

5.23

2.30

20/200 RE
20/25 LE

20/200 RE
20/250 LE

No evidence of
iridocyclitis; no
inflammatory cells in
the vitreous

No evidence of
iridocyclitis
no definite inflammatory
cells in the vitreous

FA: There was no
leakage on the FA to
suggest active CNV
OCT: RE: Disciform
scar in foveal center
involved RPE and
photoreceptor layer, no
intra retinal edema
LE: 5 lesions
surrounding foveal
center with
involvement of RPE
and disruption of the
photoreceptor layer

FA: There was no
leakage on the FA to
suggest active CNV
OCT: BE: Scars in
foveal center involved
RPE and photoreceptor
layer; no intra retinal
edema

Histoplasma Antigen: N
Histoplasma Antibody: N
RPR Screen: NR
FTA-ABS-Serum: NR
ANA Screen: P
Anti-DNA: N
RNP Antibody: N
Smith Antibody: N
Anti-RO (SS-A): N
Anti-LA (SS-B): N
Lyme Disease Antibody
(ELISA): equivocal for
antibody
Lyme Disease Antibody
(Western Blot): N

Histoplasma Antigen: N
Histoplasma Antibody: N
Muramidase (Lysozyme):
N
ACE: N
RPR Screen: NR
FTA-ABS-Serum: NR

RE: Disciform scar in
foveal center and
curvilinear distribution
of multiple chorioretinal
lesions in peripheral
retina, especially nasally
LE: curvilinear
distribution of multiple
chorioretinal lesions in
peripheral retina
especially nasal aspect
There were 5 lesions
with blurry borders
surrounding the
foveal center

BE: Peripapillary atrophy,
fibrotic scars in macula
and multiple
chorioretinal lesions in
the peripheral retina; no
subretinal fluid or heme

Past Ocular Treatment
5–6 intravitreal injections
of bevacizumab in LE
Treatment at the
Wilmer Eye Institute
Monitoring the patient
and evaluations of
tuberculosis. No IMT
was initiated

Past Ocular Treatment
Photodynamic therapy (3
times) and 4
intravitreal injections
of bevacizumab in RE.
1 intra vitreal injection
of bevacizumab in LE
Treatment at the
Wilmer Eye Institute
Intravenous
methyprednisolone
daily for 3 days.
Prednisone 60 mg/
daily for 2 weeks then
tapered to 9 mg/daily
in a period of 4 months
Mycophenolate mofetil
1,000 mg twice a day
for 3 months, then
increased to 1, 500 mg
twice a day. During the
last visit, on AF, there
appeared to be
decreased
hyperfluorescence
surrounding the lesion
in RE, especially in
nasal aspect of the
retina. AF inLE
appeared to be stable.
There was no clear
leakage seen on the
macula of either eye.

Prednisone 60 mg/daily
for 1 month tapered by
10 mg/daily every
3 weeks.
Mycophenolate mofetil
1,000 mg twice a day
and increased to 2,500
mg daily after
2 months; cyclosporine
(4 mg/kg) was also
started. During the
most recent visit, AF
did not provide any
new lesion
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FA: There was no
leakage on FA to
suggest active CNV
OCT: BE: Scar in foveal
center involved RPE
and photoreceptor
layer; no intraretinal
edema

Treatment and clinical
course
Imaging findings at
initial visit

No evidence of
iridocyclitis; no
inflammatory cells in
the vitreous
12.20
20/20 RE 20/
320 LE
20/20 RE 20/
400 LE
9/61.97/W/M/LE

Final
Initial

Bold text in the table represents clinical findings that were suggestive of active inflammation

LE: Pigmentary changes
as well as laser scar
and atrophic changes
within macula

Histoplasma Antigen: N
Histoplasma Antibody: N

Serologic findings at initial
visit
Funduscopic findings at
initial visit
AC/vitreous reaction at
initial visit
F/U
(mo)
Visual acuity

Case no./age, yr/
race/sex/affected
eye

Table 1 (continued)

F/U follow-up, AC anterior chamber, W white, F female, M male, RE right eye, LE left eye, BE both eyes, Mo month, P positive, N negative, NR nonreactive, ANA antinuclear antibody, HSV
Herpes simplex virus, ACE angiotensin-converting enzyme, RPR rapid plasma regain, FTA-ABS fluorescent treponemal antibody absorption, VZV Varicella zoster virus, EBV Epstein–Barr virus,
FA fluorescein angiography, AF auto-fluorescein, OCT optical coherence tomography, CNV choroidal neovascularization, IV intravenous, PO per oral, PED pigment epithelial detachment, IMT
immunomodulatory therapy

J Ophthal Inflamm Infect (2011) 1:55–63
Past Ocular Treatment
Laser photocoagulation
for CNV in LE
Treatment at the
Wilmer Eye Institute
The patient was
monitored as there was
no evidence of active
inflammation
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those seen in OHS were present in our patients. However,
the chorioretinal lesions resulted from inflammatory processes may be similar to those in OHS, with pigmented
borders and centers.
An enlarged blind spot at the time of presentation with
acute lesions or thereafter when the lesions are inactive has
been reported in patients with MFC [3]. For patient 5, the
Amsler visual testing revealed the presence of an old
scotoma in the nasal aspect of the field as well as a newer
small scotoma in the temporal aspect of the right visual
field. Multifocal chorioretinal lesions were seen in every
patient. The lesions were generally smaller and more
numerous than the typical histoplasma spots in OHS [4,
5]. There was a predominance of women similar to other
reports on MFC [1, 2]. The histoplasma antigen/antibody,
performed in the same laboratory was negative in all our
patients. Previously, serologic testing for Histoplasma
capsulatum used to have relatively low sensitivity with
positive result in 15% of the patients [2]. The recently
available serologic testing for H. capsulatum antigen is
highly sensitive. If it is disseminated histoplasmosis in an
immunocompetent patient, the sensitivities in serum and
urine samples are 82% and 92%, respectively; specificity is
98% and its reproducibility is excellent [6]. In those with
limited pulmonary disease, the sensitivities in serum and urine
samples are 68.6% and 64.6%, respectively [7]. In antibody
test against H. capsulatum, the positive immunodiffusion
reactions involve one or more specific precipitin bands. Of
these bands, the first to appear in active histoplasmosis is the
″M″ band, which is seen in approximately 70% of proven
cases. The M band is also seen in a number of patients with
past infections and in 20% of those with recent Histoplasma
skin testing. The ″H″ band is usually seen in active and
progressive histoplasmosis and almost always exists in the
presence of the ″M″ band, although it is found less often in
approximately 10% of proven cases (Quest Diagnostics
Nichols Institute, 14225 Newbrook Drive, Chantilly, VA
20153, and Immuno Mycologics, Inc (Immy) [8]).
Evidence of Epstein–Barr virus (EBV) infection was
detected in one of our patients, which is consistent with
Tiedeman’s report [9] about the possible relationship
between MFC and recent EBV infection.
The lesions observed in patients in the index study were
also different from those in PIC, which typically do not
have inflammatory signs, cells, or vitreous inflammation,
and often constitute a cluster of macular lesions [1]. PIC
patients have chorioretinal scars mostly in the posterior pole
and the clinical course is less likely complicated by
recurrent inflammation. The visual prognosis is usually
stable unless CNV develops. Unlike PIC, patients with
MFC have chorioretinal scars mostly in the mid-peripheral
retina and a course characterized by waxing and waning
inflammation that results in poor visual prognosis [10].

J Ophthal Inflamm Infect (2011) 1:55–63

The imaging findings in the index study supported the
MFC lesions and were consistent with the lesions described
as MFC in other studies [11, 12]. Retinal pigment epithelium
(RPE) was altered on OCT images. The hyper-fluorescent
leakage on FA images as well as hypo-fluorescence on
autofluorescene was consistent with previous descriptions of
MFC. These spots were associated with chorioretinal scars
and atrophy or absence of RPE cells detected in the posterior
pole of affected eyes [11, 12].
Once the patients were thought to have MFC with
recurrent diseases, corticosteroids and IMT were initiated,
which led to full control (no recurrences) of inflammation
and preservation of vision secondary to absence of active
inflammation [13]. IMT also allowed tapering of dosages of
corticosteroids to avoid long-term complications.
The current study emphasizes the importance of considering the possibility of other diagnoses when the disease
has atypical characteristics and behavior. Based on our
experience, when the actual chorioretinal lesions are
inflamed in the presence of an inactive CNV, the diagnosis
of OHS might be in doubt and should be reconsidered, and
different treatment approach might be required.
However, we also recognize the many limitations of our
study. The index study is a retrospective review of a small
number of patients. Many of the patients were followed for
only a short period of time. Longer follow-up time in a large
group of patients will provide more information regarding the
challenges in the diagnosis and management of MFC
masquerading as other conditions such as OHS and will also
help to confirm that treatment with IMT decreases recurrences
of diseases, as expected in MFC, and not in OHS. We also
recognize that many patients might not have presented with
appropriate information and history to aid the referring
physicians to consider MFC as possible etiologies.
Differentiation between MFC and OHS can be quite
challenging, especially when both conditions are quiescent
and there has been no previous examination or documentation
of the appearance of the fundus [1]. Serologic testing for H.
capsulatum, which is recently available with high sensitivity,
should be employed to aid in the management of such
patients, as absence of histoplasma titer and clinical characteristics of recurrent MFC may be more supportive for a
diagnosis of (inflammatory) MFC and may lead to consideration of IMT and other appropriate treatments for MFC.
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